CA2434320A1 - Chimiokines utilisees comme adjuvants de la reponse immunitaire - Google Patents
Chimiokines utilisees comme adjuvants de la reponse immunitaire Download PDFInfo
- Publication number
- CA2434320A1 CA2434320A1 CA002434320A CA2434320A CA2434320A1 CA 2434320 A1 CA2434320 A1 CA 2434320A1 CA 002434320 A CA002434320 A CA 002434320A CA 2434320 A CA2434320 A CA 2434320A CA 2434320 A1 CA2434320 A1 CA 2434320A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- mage
- chemokine
- mip
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000019034 Chemokines Human genes 0.000 title claims abstract description 89
- 108010012236 Chemokines Proteins 0.000 title claims abstract description 89
- 230000028993 immune response Effects 0.000 title claims abstract description 24
- 239000002671 adjuvant Substances 0.000 title description 7
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 194
- 239000000427 antigen Substances 0.000 claims abstract description 136
- 102000036639 antigens Human genes 0.000 claims abstract description 136
- 108091007433 antigens Proteins 0.000 claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000005012 migration Effects 0.000 claims abstract description 25
- 238000013508 migration Methods 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 43
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 43
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 38
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 36
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 35
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 35
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 30
- 108010083702 Chemokine CCL21 Proteins 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 28
- 108090000978 Interleukin-4 Proteins 0.000 claims description 21
- 102000037865 fusion proteins Human genes 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 19
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 10
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 9
- 102000003425 Tyrosinase Human genes 0.000 claims description 9
- 108060008724 Tyrosinase Proteins 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 230000002538 fungal effect Effects 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 101150016096 17 gene Proteins 0.000 claims description 8
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 8
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 8
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 claims description 8
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims description 8
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 claims description 8
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 8
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 8
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 8
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 8
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 8
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 8
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 8
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 8
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 8
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 8
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 8
- 102100034256 Mucin-1 Human genes 0.000 claims description 8
- 102100034263 Mucin-2 Human genes 0.000 claims description 8
- 102100022497 Mucin-3A Human genes 0.000 claims description 8
- 102100022693 Mucin-4 Human genes 0.000 claims description 8
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 8
- 108010017842 Telomerase Proteins 0.000 claims description 8
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims description 8
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims description 8
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- -1 DCtactin-.beta. Proteins 0.000 claims description 6
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 5
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000005210 lymphoid organ Anatomy 0.000 claims description 5
- 102100036845 C-C motif chemokine 22 Human genes 0.000 claims description 4
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 4
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 4
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims description 3
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims description 3
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 101800001271 Surface protein Proteins 0.000 claims description 3
- 102000002689 Toll-like receptor Human genes 0.000 claims description 3
- 108020000411 Toll-like receptor Proteins 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101100495057 Mus musculus Ccl25 gene Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000011645 metastatic carcinoma Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 63
- 230000004913 activation Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 52
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 47
- 230000004044 response Effects 0.000 description 40
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 33
- 102000057314 human CCL13 Human genes 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 210000001616 monocyte Anatomy 0.000 description 29
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 230000035800 maturation Effects 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 21
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 20
- 239000002243 precursor Substances 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 17
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 17
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 16
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 16
- 102000004388 Interleukin-4 Human genes 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 229940028885 interleukin-4 Drugs 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108010029697 CD40 Ligand Proteins 0.000 description 14
- 102100032937 CD40 ligand Human genes 0.000 description 14
- 102100022297 Integrin alpha-X Human genes 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 102000005936 beta-Galactosidase Human genes 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 210000001821 langerhans cell Anatomy 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 210000005208 blood dendritic cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 7
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 210000002741 palatine tonsil Anatomy 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000006023 anti-tumor response Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007115 recruitment Effects 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000001911 interdigitating cell Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010232 migration assay Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000043711 human CCL21 Human genes 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010083701 Chemokine CCL22 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 240000006108 Allium ampeloprasum Species 0.000 description 2
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 2
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 101710121996 Hexon protein p72 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000964 angiostatic effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000008349 antigen-specific humoral response Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012950 reanalysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100021661 Aryl hydrocarbon receptor nuclear translocator-like protein 2 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 101710112540 C-C motif chemokine 25 Proteins 0.000 description 1
- 108010061300 CXCR3 Receptors Proteins 0.000 description 1
- 102000011963 CXCR3 Receptors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000984642 Cura Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000896221 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 2 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GVQYIMKPSDOTAH-UHFFFAOYSA-N NCC 1 Natural products CC1=C(C=C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(C2C=3NC(CC4=C(C(C)=C(C=O)N4)CCOC(=O)CC(O)=O)=C(C)C=3C(=O)C2C(O)=O)N1 GVQYIMKPSDOTAH-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000010002 chemokinesis Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005135 veiled cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
Abstract
Selon la présente invention, les cellules dendritiques jouent un rôle déterminant dans les réponses immunitaires spécifiques aux antigènes. Cette invention concerne des substances et des méthodes destinées à traiter des états pathologiques, tels que le cancer et les maladies auto-immunes, en favorisant ou en inhibant la migration ou l'activation de cellules dendritiques de présentation antigénique. Plus particulièrement, on utilise des chimiokines pour induire, amplifier ou moduler une réponse immunitaire. Dans un mode de réalisation, ces chimiokines sont utilisées pour attirer des cellules dendritiques vers le site d'administration d'antigènes. Un nombre accru de cellules dendritiques au niveau du site d'administration d'antigènes indique une augmentation de l'absorption antigénique et une modification de la réponse immunitaire.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/768,917 US7217700B2 (en) | 1998-07-16 | 2001-01-24 | Chemokines as adjuvants of immune response |
US09/768,917 | 2001-01-24 | ||
PCT/US2002/001849 WO2002058723A2 (fr) | 2001-01-24 | 2002-01-22 | Chimiokines utilisees comme adjuvants de la reponse immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2434320A1 true CA2434320A1 (fr) | 2002-08-01 |
Family
ID=25083870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002434320A Abandoned CA2434320A1 (fr) | 2001-01-24 | 2002-01-22 | Chimiokines utilisees comme adjuvants de la reponse immunitaire |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1392351A2 (fr) |
JP (2) | JP2004520043A (fr) |
CA (1) | CA2434320A1 (fr) |
MX (1) | MXPA03006587A (fr) |
WO (1) | WO2002058723A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046748A1 (fr) * | 2003-11-12 | 2005-05-26 | James Keenan | Dispositif et procede pour attirer des cellules malades et des substances etrangeres |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077247A1 (en) * | 2001-09-20 | 2003-04-24 | Schering Corporation | Chemokines as adjuvants of immune response |
WO2003035106A1 (fr) * | 2001-10-24 | 2003-05-01 | Chemocentryx | Procedes et compositions servant a induire une reponse immune |
EP1599572A4 (fr) * | 2003-02-14 | 2007-06-13 | Univ Southern California | Compositions et methodes pour immunotherapie anticancereuse |
US20040191215A1 (en) * | 2003-03-25 | 2004-09-30 | Michael Froix | Compositions for induction of a therapeutic response |
CN100342017C (zh) * | 2004-05-10 | 2007-10-10 | 中国医学科学院肿瘤医院肿瘤研究所 | 基因重组趋化抗原疫苗 |
EP2347774B1 (fr) | 2005-12-13 | 2017-07-26 | The President and Fellows of Harvard College | Echafaudages pour transplantation cellulaire |
WO2009002401A2 (fr) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Échafaudages pour recueil ou élimination de cellules |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
WO2011014871A1 (fr) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programmation de cellules à des fins de thérapie tolérogénique |
JP6104806B2 (ja) | 2010-10-06 | 2017-03-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル |
US10045947B2 (en) | 2011-04-28 | 2018-08-14 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
US9486512B2 (en) | 2011-06-03 | 2016-11-08 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
EP2838515B1 (fr) | 2012-04-16 | 2019-11-20 | President and Fellows of Harvard College | Compositions de silice mésoporeuse pour moduler les réponses immunitaires |
JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
EP3250250A4 (fr) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Matériaux péritumoraux et intratumoraux pour traitement anticancéreux |
JP7094533B2 (ja) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫細胞捕捉デバイスおよびその製造および使用方法 |
JP7138864B2 (ja) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫を再構成するための造血ニッチの再現 |
US10980877B2 (en) * | 2016-04-28 | 2021-04-20 | The University Of Chicago | Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen |
CN109789092A (zh) | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
US11419928B2 (en) | 2017-10-25 | 2022-08-23 | The Johns Hopkins University | Methods and compositions for treating cancer |
WO2019094938A2 (fr) | 2017-11-13 | 2019-05-16 | The University Of Chicago | Méthodes et compositions pour le traitement des plaies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562347B1 (en) * | 1998-03-12 | 2003-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Chemokine-tumor antigen fusion proteins as cancer vaccines |
EP0974357A1 (fr) * | 1998-07-16 | 2000-01-26 | Schering-Plough | Chemokines comme adjuvants de la réponse immunitaire |
-
2002
- 2002-01-22 CA CA002434320A patent/CA2434320A1/fr not_active Abandoned
- 2002-01-22 WO PCT/US2002/001849 patent/WO2002058723A2/fr active Application Filing
- 2002-01-22 MX MXPA03006587A patent/MXPA03006587A/es not_active Application Discontinuation
- 2002-01-22 EP EP02705895A patent/EP1392351A2/fr not_active Withdrawn
- 2002-01-22 JP JP2002559057A patent/JP2004520043A/ja active Pending
-
2008
- 2008-02-04 JP JP2008024609A patent/JP2008133296A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046748A1 (fr) * | 2003-11-12 | 2005-05-26 | James Keenan | Dispositif et procede pour attirer des cellules malades et des substances etrangeres |
Also Published As
Publication number | Publication date |
---|---|
JP2008133296A (ja) | 2008-06-12 |
EP1392351A2 (fr) | 2004-03-03 |
WO2002058723A2 (fr) | 2002-08-01 |
MXPA03006587A (es) | 2003-09-22 |
JP2004520043A (ja) | 2004-07-08 |
WO2002058723A3 (fr) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070128159A1 (en) | Chemokines as adjuvants of immune response | |
CA2434320A1 (fr) | Chimiokines utilisees comme adjuvants de la reponse immunitaire | |
Furumoto et al. | Induction of potent antitumor immunity by in situ targeting of intratumoral DCs | |
Mocellin et al. | Cytokines and immune response in the tumor microenvironment | |
Kirk et al. | T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy | |
Guiducci et al. | Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection | |
Yang et al. | Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity | |
Benchetrit et al. | Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism | |
US20070166280A1 (en) | Chemokines as adjuvants of immune response | |
EP1255554B1 (fr) | Vaccin contre les tumeurs specifiques du rein, dirige contre l'antigene g-250 de la tumeur du rein | |
EP1368061A2 (fr) | Cellules de fusion et compositions cytokiniques pour le traitement de maladies | |
AU2002225990A1 (en) | Fusion cells and cytokine compositions for treatment of disease | |
Hüttner et al. | Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells | |
JP2007523901A (ja) | 癌治療のための融合細胞とインターロイキン−12の複合免疫療法 | |
US20030008840A1 (en) | Methods for treating cancer | |
Liu et al. | Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity | |
Weigel et al. | Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses | |
US20020114812A1 (en) | Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor | |
Pajtasz-Piasecka et al. | Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes | |
Neeson et al. | Effects of the tumor microenvironment on the efficacy of tumor immunotherapy | |
Kwon et al. | Co-expression of bfl-1 enhances host response in the herpes simplex virus-thymidine kinase/ganciclovir gene therapy system | |
CA3019999A1 (fr) | Vaccins anticancereux a base de microparticules de silicium poreux et procedes de potentialisation de l'immunite anti-tumorale | |
Terando et al. | Enhancing dendritic cell-based vaccines by gene modification | |
WO2023192542A1 (fr) | Compositions et procédés pour activation de cellules immunitaires | |
Cicchelero | Mono-and combination immunotherapy in dogs with spontaneous tumors: stimulation of the adaptive and innate immune system against cancer and suppression of immunosuppressive immune cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |